Sugi Predict
/ Targets
/ PIM1
Top predicted compounds (top 20 by supporting neighbours, then confidence)
Clinical trials — most relevant to PIM1 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab |
PHASE4 | UNKNOWN |
| Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy |
PHASE3 | COMPLETED |
| A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL |
PHASE1/PHASE2 | RECRUITING |
| Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer |
PHASE2 | UNKNOWN |
| A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer |
PHASE2 | RECRUITING |
| Pembrolizumab (MK-3475) in MM Patients With Residual Disease |
PHASE2 | COMPLETED |
| A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. |
PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING |
| Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma |
PHASE1/PHASE2 | SUSPENDED |
| PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma |
PHASE2 | UNKNOWN |
| Study in Adult Ph-positive ALL |
PHASE2 | UNKNOWN |
| Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer |
PHASE2 | UNKNOWN |
| A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer |
PHASE2 | NOT_YET_RECRUITING |
| MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 |
PHASE2 | COMPLETED |
| Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias |
PHASE1 | WITHDRAWN |
| A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects |
PHASE1 | COMPLETED |
| A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects |
PHASE1 | COMPLETED |
| Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer |
PHASE1 | UNKNOWN |
| Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis |
PHASE1 | COMPLETED |
| Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer |
PHASE1 | WITHDRAWN |
| A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects |
PHASE1 | COMPLETED |
| Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy |
PHASE1 | UNKNOWN |
| Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients |
PHASE1 | COMPLETED |
| A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers |
PHASE1 | COMPLETED |
| Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) |
PHASE1 | COMPLETED |
| Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer |
PHASE1 | ACTIVE_NOT_RECRUITING |
| Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer |
PHASE1 | WITHDRAWN |
| The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function |
PHASE1 | COMPLETED |
| Evaluation of Hypoxia in Primary Melanoma |
nan | RECRUITING |
| p-AKT Expression on Clinical Outcomes in Malignant Lymphoma |
nan | COMPLETED |
Related proteins — ESM-2 sequence neighbours (a PIM1 binder may also engage these)